These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32581257)

  • 21. Sex-dependent pharmacokinetics of indinavir: in vivo and in vitro evidence.
    Lin JH; Chiba M; Chen IW; Nishime JA; Vastag KJ
    Drug Metab Dispos; 1996 Dec; 24(12):1298-306. PubMed ID: 8971134
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolism and clinical pharmacokinetics of 2-methyl-n-(2'-(pyrrolidinyl-1-ylsulfonyl)-n-[1,1'-biphenyl]-4-yl)propran-1-amine: insights into monoamine oxidase- and CYP-mediated disposition by integration of in vitro ADME tools.
    Sawant Basak A; Byon W; Tseng-Lovering E; Funk C; Wood L; Lin C; Delnomdedieu M; Verhoest P; Parikh V; Cox LM; Miller E; Gao H; Obach RS
    Xenobiotica; 2014 May; 44(5):438-54. PubMed ID: 24304147
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil.
    Lee HS; Park EJ; Ji HY; Kim SY; Im GJ; Lee SM; Jang IJ
    Xenobiotica; 2008 Jan; 38(1):21-33. PubMed ID: 18098061
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metabolism, excretion, and pharmacokinetics of ((3,3-difluoropyrrolidin-1-yl)((2S,4S)-4-(4-(pyrimidin-2-yl)piperazin-1-yl)pyrrolidin-2-yl)methanone, a dipeptidyl peptidase inhibitor, in rat, dog and human.
    Sharma R; Sun H; Piotrowski DW; Ryder TF; Doran SD; Dai H; Prakash C
    Drug Metab Dispos; 2012 Nov; 40(11):2143-61. PubMed ID: 22896728
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolism of tauromustine in liver and lung microsomes from various species.
    Tuvesson H; Gunnarsson PO; Seidegård J
    Xenobiotica; 1999 Aug; 29(8):783-92. PubMed ID: 10553719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Metabolite elucidation of the Hsp90 inhibitor SNX-2112 using ultraperformance liquid chromatography/quadrupole time-of-flight mass spectrometry (UPLC-QTOF/MS).
    Liu W; Liu H; Sun H; Dong D; Ma Z; Wang Y; Wu B
    Xenobiotica; 2014 May; 44(5):455-64. PubMed ID: 24191862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Species differences in the pharmacokinetics and metabolism of indinavir, a potent human immunodeficiency virus protease inhibitor.
    Lin JH; Chiba M; Balani SK; Chen IW; Kwei GY; Vastag KJ; Nishime JA
    Drug Metab Dispos; 1996 Oct; 24(10):1111-20. PubMed ID: 8894513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs.
    Zhou X; Gao ZW; Meng J; Chen XY; Zhong DF
    Acta Pharmacol Sin; 2013 Nov; 34(11):1420-6. PubMed ID: 24056704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significant species difference in amide hydrolysis of GDC-0834, a novel potent and selective Bruton's tyrosine kinase inhibitor.
    Liu L; Halladay JS; Shin Y; Wong S; Coraggio M; La H; Baumgardner M; Le H; Gopaul S; Boggs J; Kuebler P; Davis JC; Liao XC; Lubach JW; Deese A; Sowell CG; Currie KS; Young WB; Khojasteh SC; Hop CE; Wong H
    Drug Metab Dispos; 2011 Oct; 39(10):1840-9. PubMed ID: 21742900
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro ketamine CYP3A-mediated metabolism study using mammalian liver S9 fractions, cDNA expressed enzymes and liquid chromatography tandem mass spectrometry.
    Santamaria R; Pailleux F; Beaudry F
    Biomed Chromatogr; 2014 Dec; 28(12):1660-9. PubMed ID: 24729431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Formation in vitro of an inhibitory cytochrome P450 x Fe2+-metabolite complex with roxithromycin and its decladinosyl, O-dealkyl and N-demethyl metabolites in rat liver microsomes.
    Yamazaki H; Shimada T
    Xenobiotica; 1998 Oct; 28(10):995-1004. PubMed ID: 9849646
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of capravirine as a CYP3A probe substrate: in vitro and in vivo metabolism of capravirine in rats and dogs.
    Bu HZ; Zhao P; Kang P; Pool WF; Wu EY; Shetty BV
    Drug Metab Dispos; 2007 Sep; 35(9):1593-602. PubMed ID: 17567732
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates.
    Zhao K; Ding M; Cao H; Cao ZX
    J Pharm Pharmacol; 2012 Oct; 64(10):1445-51. PubMed ID: 22943175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interaction with indinavir to enhance systemic exposure of an investigational HIV protease inhibitor in rats, dogs and monkeys.
    Jin L; Chen IW; Chiba M; Lin JH
    Xenobiotica; 2003 Jun; 33(6):643-54. PubMed ID: 12851040
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Study of the in vitro metabolism of TJ0711 using ultra high performance liquid chromatography with quadrupole time-of-flight and ultra fast liquid chromatography with quadrupole linear ion trap mass spectrometry.
    Hu L; Lv Z; Li G; Xu X; Zhang C; Cao P; Huang J; Si L
    J Sep Sci; 2015 Jun; 38(11):1837-49. PubMed ID: 25800512
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor.
    Mosure KW; Knipe JO; Browning M; Arora V; Shu YZ; Phillip T; Mcphee F; Scola P; Balakrishnan A; Soars MG; Santone K; Sinz M
    J Pharm Sci; 2015 Sep; 104(9):2813-23. PubMed ID: 25631585
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparative metabolism of aschantin in human and animal hepatocytes.
    Lee MS; Shim HJ; Cho YY; Lee JY; Kang HC; Song IS; Lee HS
    Arch Pharm Res; 2024 Feb; 47(2):111-126. PubMed ID: 38182943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biotransformation of 6-methoxy-3-(3',4',5'-trimethoxy-benzoyl)-1H-indole (BPR0L075), a novel antimicrotubule agent, by mouse, rat, dog, and human liver microsomes.
    Yao HT; Wu YS; Chang YW; Hsieh HP; Chen WC; Lan SJ; Chen CT; Chao YS; Chang L; Sun HY; Yeh TK
    Drug Metab Dispos; 2007 Jul; 35(7):1042-9. PubMed ID: 17403915
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Main metabolic pathways of TAK-802, a novel drug candidate for voiding dysfunction, in humans: the involvement of carbonyl reduction by 11β-hydroxysteroid dehydrogenase 1.
    Nishihara M; Takahashi J; Kondo T; Mouri K; Asahi S
    Drug Res (Stuttg); 2014 Sep; 64(9):476-84. PubMed ID: 24357138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacokinetics and disposition of anlotinib, an oral tyrosine kinase inhibitor, in experimental animal species.
    Zhong CC; Chen F; Yang JL; Jia WW; Li L; Cheng C; Du FF; Zhang SP; Xie CY; Zhang NT; Olaleye OE; Wang FQ; Xu F; Lou LG; Chen DY; Niu W; Li C
    Acta Pharmacol Sin; 2018 Jun; 39(6):1048-1063. PubMed ID: 29620050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.